香港醫思醫療集團(02138.HK)參與香港新冠病毒疫苗接種計劃
格隆匯3月4日丨香港醫思醫療集團(02138.HK)公吿稱,作為香港最大的非醫院醫療服務提供商,董事會特吿知股東和潛在投資者,集團為市民的健康及福祉致力,全力支持香港政府有關新冠病毒疫苗接種安排,與市民一起抗擊疫症。
集團13名從業醫生已經註冊參加香港政府的新冠病毒疫苗接種計劃。經批准的科興生物“CoronaVac”疫苗注射將於集團位處香港的醫療中心提供予5個優先組別的人士。
公司表示,集團擁有香港政府“麻疹疫苗撲滅計劃”及“季節性流感疫苗補貼計劃”的疫苗接種經驗。集團將利用領先的醫療專業水平,出色的醫療環境條件和發達的資訊科技基礎設施,與香港政府積極合作,提供有關新冠病毒疫苗接種服務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.